-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
Hydroxychloroquine Sulfate
![{PARAM:[Name]}({[CAS]})](https://resource.bocsci.com/structure/747-36-4.gif)
| Category | SARS-CoV |
| CAS | 747-36-4 |
| Description | Hydroxychloroquine Sulfate is an autophagy inhibitor that induces autophagic cell death. It also inhibits TLR9. Hydroxychloroquine is an antimalarial drug, and in combination with other medications, it can be used in the treatment of some autto-immune diseases. It has been used in emergency of COVID-19. |
Product Information
| Synonyms | 2-[[4-[(7-Chloro-4-quinolinyl)amino]pentyl]ethylamino]ethanol sulfate |
| IUPAC Name | 2-[4-[(7-chloroquinolin-4-yl)amino]pentyl-ethylamino]ethanol;sulfuric acid |
| Molecular Weight | 433.95 |
| Molecular Formula | C18H28ClN3O5S |
| Canonical SMILES | CC(CCCN(CC)CCO)NC1=CC=NC2=CC(Cl)=CC=C21.O=S(O)(O)=O |
| InChI | 1S/C18H26ClN3O.H2O4S/c1-3-22(11-12-23)10-4-5-14(2)21-17-8-9-20-18-13-15(19)6-7-16(17)18;1-5(2,3)4/h6-9,13-14,23H,3-5,10-12H2,1-2H3,(H,20,21);(H2,1,2,3,4) |
| InChIKey | JCBIVZZPXRZKTI-UHFFFAOYSA-N |
| Boiling Point | 516.7 °C at 760 mmHg |
| Melting Point | 240 °C |
| Flash Point | 266.3°C |
| Purity | > 95% |
| Solubility | Soluble to 100 mM in water |
| Appearance | White lyophilised solid |
| Storage | Store at +4°C |
| Animal Admin | MRL/lpr mice are dosed orally five times a week with 20 or 60 mg/kg E6446 or 60 mg/kg Hydroxychloroquine sulfate beginning at 5 weeks of age. Cytoxan is administered at 50 mg/kg i.p. every 10 days. A serum sample is taken immediately before the beginning of treatment to monitor changes in autoreactive antibodies. Subsequently, serum samples are collected approximately monthly and analyzed for anti-dsDNA by ELISA after 1:500 dilution. Body weights and urine samples are taken at the same interval, and proteinuria is assessed. Anti-nuclear antibodies (ANA) are assessed using commercially available HEp2 slide kits, with serum diluted to 1:100 in kit buffer. ANA scores are read blinded. |
| In Vitro | Hydroxychloroquine sulfate is a synthetic antimalarial drug derived from 4-aminoquinoline; it has been used for several decades for the treatment of some rheumatic diseases such as rheumatoid arthritis (RA). Five micromolar Hydroxychloroquine sulfate or chloroquine also has no measurable effect on intracellular pH, although these concentrations can inhibit TLR9 or 7 signaling induced by DNA or RNA ligands. |
| In Vivo | Hydroxychloroquine sulfate is prescribed for the treatment of lupus, and both Hydroxychloroquine sulfate and its analog chloroquine inhibit TLR7 and 9 signaling. |
| PSA | 131.37 |
| Target | SARS-CoV |